Sanofi Consumer Healthcare India: net profit ₹766 mn, up 22%, per the 28 October 2026 filing (NSE: SANOFICONR)
Sanofi Consumer Healthcare India (NSE: SANOFICONR; BSE: 544250) reported revenue of ₹2,631 million and net profit of ₹766 million in its results filing dated 28 October 2026 — up 12% and 22% year on year, both as stated in that filing. The filing attributes the quarter to domestic volume-led growth, with relaunch benefits extending the margin uptrend.
Sanofi Consumer Healthcare India (NSE: SANOFICONR; BSE: 544250) reported revenue of ₹2,631 million and net profit of ₹766 million in its results filing dated 28 October 2026 — up 12% and 22% year on year, both as stated in that filing. The filing attributes the quarter to domestic volume-led growth, with relaunch benefits extending the margin uptrend.
It continues a run of filings dating back to June, all pointing the same way. What follows is the sequence as filed, with the places where the documents disagree left visible.
29 June 2026: a statutory auditor, and the only stated period in the set
Shareholders at the third AGM approved Price Waterhouse & Co Chartered Accountants LLP as statutory auditor — first filling a casual vacancy created by the resignation of Kalyaniwalla & Mistry LLP, then for a five-year term. From the governance filing dated 29 June 2026:
"Shareholders at the 3rd AGM approved the appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as statutory auditor, initially filling a casual vacancy from the resignation of Kalyaniwalla & Mistry LLP, and then for a five-year term through the 2031 AGM."
The 2031 AGM is the only stated future period anywhere in this set of documents.
28 July 2026: three results filings, one direction
Three results documents were filed that day, each with its own period label and its own figures. They are reported below as filed. The underlying P&L is not in this data, so nothing has been reconciled or recalculated.
- Labelled Q1FY27: PAT ₹68.8 Cr, up 13% YoY, on revenue of ₹235.7 Cr, up 6.7% YoY, with the domestic relaunch cited.
- Labelled Q2'26: revenue ₹2,357 Mn, up 7% YoY; PAT ₹688 Mn, up 13% YoY; EBITDA margin 39.0%, up 130 bps YoY, on cost optimisation.
- Labelled Q2FY26: gross margin up 380 bps; EBITDA margin 40.6%, up 630 bps YoY; net profit up 13.3% YoY.
Two margin readings from the same date — 39.0% and 40.6% — do not match, and the filings in this set do not explain why. The period labels do not match either. What is consistent: in all three, profit growth outpaces revenue growth, and each document ties the improvement to the domestic business and to cost lines.
28 October 2026: 22% profit growth on 12% revenue growth
The October filing reports revenue of ₹2,631 million, up 12% YoY, and net profit of ₹766 million, up 22% YoY. Profit growth again runs ahead of revenue growth. The description of the driver shifts too — the July filings have the domestic relaunch behind the margin improvement; the October filing has relaunch benefits extending the margin uptrend.
What is not in these filings
No revenue guidance, margin guidance or capital-allocation commitment appears in any of the documents above. Apart from the auditor's term through the 2031 AGM, the company states no future period in this set. The units also differ between filings — ₹ Cr in the July documents, ₹ Mn in the October one — and nothing here has been converted; each figure stands as its source document states it.
Alpha Inflection is research infrastructure, not investment advice. We are not SEBI-registered investment advisers. Everything above is compiled from public corporate filings, with sources cited. Do your own research.
The filing evidence
| Date | What the filing said | Detail | Source |
|---|---|---|---|
| 28 Jul 2026 | Q1FY27 PAT up 13% YoY to ₹68.8 Cr on revenue of ₹235.7 Cr (+6.7% YoY) as domestic relaunch drives margin expansion | filing | |
| 28 Jul 2026 | Q2'26 revenue ₹2,357 Mn, +7% YoY; PAT ₹688 Mn, +13% YoY; EBITDA margin expanded 130 bps YoY to 39.0% on cost optimisation; a clean beat on profit growth. | filing | |
| 28 Jul 2026 | Sanofi Consumer Healthcare Q2FY26: Domestic rebound drives 6.7% revenue growth; gross margin expands 380bps, EBITDA margin surges 630bps to 40.6%; net profit up 13.3% YoY. | filing | |
| 28 Oct 2026 | Revenue ₹2,631 million rose 12% YoY and net profit reached ₹766 million, up 22%; domestic volume-led growth and relaunch benefits are extending the margin uptrend. | filing | |
| 29 Jun 2026 | Sanofi Consumer Healthcare India appoints Price Waterhouse & Co as statutory auditor to fill casual vacancy and for a five-year term | Shareholders at the 3rd AGM approved the appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as statutory auditor, initially filling a casual vacancy from the resignation of Kalyaniwalla & Mistry LLP, and then for a five-year term through the 2031 AGM. | filing |
Quick answers
- What did Sanofi Consumer disclose?
- Sanofi Consumer Healthcare India (NSE: SANOFICONR; BSE: 544250) reported revenue of ₹2,631 million and net profit of ₹766 million in its results filing dated 28 October 2026 — up 12% and 22% year on year, both as stated in that filing. The filing attributes the quarter to domestic volume-led growth, with relaunch benefits extending the margin uptrend.
- What are the key numbers?
- The October filing reports revenue of ₹2,631 million, up 12% YoY, and net profit of ₹766 million, up 22% YoY. Profit growth again runs ahead of revenue growth. The description of the driver shifts too — the July filings have the domestic relaunch behind the margin improvement; the October filing has relaunch benefits extending the margin uptrend.
- What does Sanofi Consumer say comes next?
- No revenue guidance, margin guidance or capital-allocation commitment appears in any of the documents above. Apart from the auditor's term through the 2031 AGM, the company states no future period in this set.
Research and educational content only. Not investment advice. Drafted from regulatory filings and published automatically — see our editorial policy.